Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTRAMUSCULAR INJECTIONS OF SLOW-RELEASE LANREOTIDE (BIM-23014) IN ACROMEGALIC PATIENTS PREVIOUSLY TREATED WITH CONTINUOUS SUBCUTANEOUS INFUSION OF OCTREOTIDE (SMS-201-995)
Autore:
CARON P; COGNE M; GUSTHIOTJOUDET B; WAKIM S; CATUS F; BAYARD F;
Indirizzi:
CHU RANGUEIL,DEPT ENDOCRINOL,SERV ENDOCRINOL & MALAD METAB,1 AVE J POULHES F-31054 TOULOUSE FRANCE IPSEN BIOTECH LAB PARIS FRANCE
Titolo Testata:
European journal of endocrinology
fascicolo: 3, volume: 132, anno: 1995,
pagine: 320 - 325
SICI:
0804-4643(1995)132:3<320:IIOSL(>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
SOMATOSTATIN ANALOG OCTREOTIDE; GROWTH-HORMONE RESPONSES; SOMATOMEDIN-C LEVELS; LONG-TERM TREATMENT; PITUITARY-ADENOMAS; BROMOCRIPTINE; RECEPTORS; THERAPY; PHARMACOKINETICS; GH;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
P. Caron et al., "INTRAMUSCULAR INJECTIONS OF SLOW-RELEASE LANREOTIDE (BIM-23014) IN ACROMEGALIC PATIENTS PREVIOUSLY TREATED WITH CONTINUOUS SUBCUTANEOUS INFUSION OF OCTREOTIDE (SMS-201-995)", European journal of endocrinology, 132(3), 1995, pp. 320-325

Abstract

Nine acromegalic patients (five females and four males), mean age 50+/-4 years, presented macroadenomas (N = 7), microadenoma (N = 1) or normal computed tomography scans (N = 1). Patients were treated with continuous subcutaneous infusion of octreotide (range 200-600 mu g/day). Following a washout period of 7 days, the patients were injected im with 30 mg slow-release lanreotide every 10 days for the first month andthen twice monthly. In case of elevated growth hormone (GH) levels at3 months, the patients were injected every 10 days for the next threemonths. Plasma GH and insulin-like growth factor I (IGH-I) decreased in all patients during octreotide treatment. After 6 months of octreotide treatment, seven patients were considered as well controlled (mean8 h GH < 5 mu g/l, IGF-I normal) whereas in two patients the mean 8-hGH and/or IGF-I levels remained increased. Serum GH and IGH-I increased after octreotide withdrawal. In one patient, serum GH and IGF-I increased during slow-release lanreotide administration and injections were stopped after 45 days. After 3 months of lanreotide, three patientswere well controlled while in five patients GH or IGF-I levels were not normalized. At 6 months, five patients were injected twice monthly and three patients had one injection every 10 days. Six patients were well controlled and in two patients the mean 8-h GH level remained increased. The pituitary tumor volume decreased by 20-30% in two patientsduring octreotide, as well as in one other during slow-release lanreotide therapy. Slow-release lanreotide was well tolerated except for minor digestive problems during the early days of treatment or mild painat the site of injection. Gallbladder echographies were normal duringoctreotide and lanreotide therapies, except in one patient in whom gallstones occurred during octreotide treatment. In conclusion, this clinical study shows that in acromegalic patients, im injections of slow-release lanreotide (two or three per month) are well tolerated and areas effective as continuous subcutaneous infusion of octreotide in thecontrol of GH hypersecretion. Therefore, slow-release lanreotide would appear to be a useful therapeutic tool to improve the quality of life in patients with acromegaly.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 22:28:23